- Home
- OTLK vs ZDGE Comparison
OTLK vs ZDGE Comparison
Compare OTLK & ZDGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- ZDGE
- Stock Information
- Founded
- OTLK 2010
- ZDGE 2008
- Country
- OTLK United States
- ZDGE United States
- Employees
- OTLK N/A
- ZDGE N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- ZDGE Computer Software: Prepackaged Software
- Sector
- OTLK Health Care
- ZDGE Technology
- Exchange
- OTLK Nasdaq
- ZDGE Nasdaq
- Market Cap
- OTLK 48.3M
- ZDGE 40.3M
- IPO Year
- OTLK 2016
- ZDGE N/A
- Fundamental
- Price
- OTLK $1.77
- ZDGE $2.43
- Analyst Decision
- OTLK Strong Buy
- ZDGE
- Analyst Count
- OTLK 5
- ZDGE 0
- Target Price
- OTLK $10.20
- ZDGE N/A
- AVG Volume (30 Days)
- OTLK 689.4K
- ZDGE 25.9K
- Earning Date
- OTLK 05-15-2025
- ZDGE 06-12-2025
- Dividend Yield
- OTLK N/A
- ZDGE N/A
- EPS Growth
- OTLK N/A
- ZDGE N/A
- EPS
- OTLK 0.83
- ZDGE N/A
- Revenue
- OTLK N/A
- ZDGE $29,412,000.00
- Revenue This Year
- OTLK N/A
- ZDGE N/A
- Revenue Next Year
- OTLK $288.46
- ZDGE $1.07
- P/E Ratio
- OTLK $2.12
- ZDGE N/A
- Revenue Growth
- OTLK N/A
- ZDGE 4.26
- 52 Week Low
- OTLK $0.87
- ZDGE $1.73
- 52 Week High
- OTLK $9.25
- ZDGE $4.38
- Technical
- Relative Strength Index (RSI)
- OTLK 57.64
- ZDGE 55.32
- Support Level
- OTLK $1.55
- ZDGE $2.12
- Resistance Level
- OTLK $1.90
- ZDGE $2.50
- Average True Range (ATR)
- OTLK 0.18
- ZDGE 0.13
- MACD
- OTLK 0.01
- ZDGE 0.01
- Stochastic Oscillator
- OTLK 53.10
- ZDGE 75.61
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About ZDGE Zedge Inc. Class B
Zedge Inc provides content distribution platforms. Its content platform enables consumers to personalize their mobile devices with free, high-quality ringtones, wallpapers, home screen app icons, widgets and notification sounds as well as paint, a generative AI wallpaper maker, GuruShots, a skill-based photo challenge game, and Emojipedia. The company also launched a Zedge app. It has two reportable segments, which are the Zedge Marketplace and GuruShots.